Begonya Comin-Anduix

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    Franziska Niehr
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
    J Transl Med 9:76. 2011
  2. pmc Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Jonas N Søndergaard
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 8:39. 2010
  3. pmc Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma
    Begona Comin-Anduix
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 5:e12711. 2010
  4. pmc Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 6:22. 2008
  5. ncbi request reprint Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
  6. pmc CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    Erika von Euw
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
    J Transl Med 7:35. 2009
  7. pmc BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer Res 72:3928-37. 2012
  8. pmc T-cell responses to survivin in cancer patients undergoing radiation therapy
    Dorthe Schaue
    Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California 90095 1714, USA
    Clin Cancer Res 14:4883-90. 2008
  9. pmc Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
    Mohammad Atefi
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e28973. 2011
  10. doi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009

Collaborators

Detail Information

Publications23

  1. pmc Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations
    Franziska Niehr
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles UCLA, USA
    J Transl Med 9:76. 2011
    ..A molecular linkage between the MAPK and the LKB1-AMPK energy sensor pathways suggests that combined MAPK oncogene inhibition and metabolic modulation of AMPK would be more effective than either manipulation alone in melanoma cell lines...
  2. pmc Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
    Jonas N Søndergaard
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 8:39. 2010
    ..In conclusion, BRAFV600E mutant melanoma cell lines displayed a range of sensitivities to PLX4032 and metabolic imaging using PET probes can be used to assess sensitivity...
  3. pmc Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma
    Begona Comin-Anduix
    Division of Surgical Oncology, Department of Surgery, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 5:e12711. 2010
    ....
  4. pmc Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical Oncology, University of California Los Angeles, Los Angeles, CA, USA
    J Transl Med 6:22. 2008
    ..CTLA4-blocking antibodies induce tumor regression in a subset of patients with melanoma. Analysis of immune parameters in peripheral blood may help define how responses are mediated...
  5. ncbi request reprint Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology, University of California, Los Angeles, CA 90095, USA
    J Immunol 172:4762-9. 2004
    ..Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches...
  6. pmc CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
    Erika von Euw
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles, Los Angeles, California, USA
    J Transl Med 7:35. 2009
    ..We studied the levels of this T cell subset in peripheral blood of patients treated with the anti-CTLA4 antibody tremelimumab since its major dose limiting toxicities are inflammatory and autoimmune in nature...
  7. pmc BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy
    Richard C Koya
    Department of Surgery, Division of Surgical Oncology, Crump Institute for Molecular Imaging, UCLA Biomedical Physics Interdepartmental Graduate Program, Los Angeles, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Cancer Res 72:3928-37. 2012
    ..Taken together, our findings, derived from 2 independent models combining BRAF-targeted therapy with immunotherapy, support the testing of this therapeutic combination in patients with BRAFV600 mutant metastatic melanoma...
  8. pmc T-cell responses to survivin in cancer patients undergoing radiation therapy
    Dorthe Schaue
    Department of Radiation Oncology, University of California at Los Angeles, Los Angeles, California 90095 1714, USA
    Clin Cancer Res 14:4883-90. 2008
    ..The goal of this study was to determine if radiation therapy (RT) of human cancer enhances or diminishes tumor-specific T-cell reactivity. This is important if immunotherapy is to be harnessed to improve the outcome of cancer radiotherapy...
  9. pmc Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
    Mohammad Atefi
    Department of Medicine, Division of Hematology Oncology, University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e28973. 2011
    ..Clinical trials are in progress using MEK inhibitors following disease progression in patients receiving BRAF inhibitors. However, the PI3K/AKT pathway can also induce resistance to the inhibitors of MAPK pathway...
  10. doi request reprint Immunosensitization with a Bcl-2 small molecule inhibitor
    Jonathan Begley
    Department of Surgery, University of California at Los Angeles, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095 1782, USA
    Cancer Immunol Immunother 58:699-708. 2009
    ....
  11. ncbi request reprint Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells
    Jennifer A Wargo
    Department of Surgery, Division of Surgical Oncology, University of California at Los Angeles, Los Angeles, CA 90095, USA
    Cancer Gene Ther 12:516-27. 2005
    ..In conclusion, protective immunity after tumor antigen gene-modified DC immunization requires collaboration between CD4+ and CD8+ T cells and NK cells...
  12. doi request reprint Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial
    Antoni Ribas
    Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA 90095, USA
    Clin Cancer Res 17:2987-96. 2011
    ..The goal of this study was to test the safety and activity of a therapeutic vaccine, MKC1106-MT, in patients with metastatic melanoma...
  13. pmc A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells
    Chao Ma
    NanoSystems Biology Cancer Center, California Institute of Technology, Pasadena, California, USA
    Nat Med 17:738-43. 2011
    ..The platform represents a new and informative tool for immune monitoring and clinical assessment...
  14. ncbi request reprint Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression
    Takahiro Kimura
    Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California, USA
    Mol Ther 15:1390-9. 2007
    ..These studies reveal that APC transduction by LVs could lead to immune reactivity (LV-CMV) or persistence of transgene expression (LV-MHCII), providing a relevant paradigm for vaccination and gene replacement approaches...
  15. ncbi request reprint Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy
    Antoni Ribas
    Department of Surgery, Division of Surgical Oncology, UCLA Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California, USA
    J Immunother 27:354-67. 2004
    ..Sequential CTLA4 blockade may enhance the immune activity of DC-based immunotherapy...
  16. doi request reprint Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, California 90095 1782, USA
    Clin Cancer Res 15:390-9. 2009
    ..In this study, biopsies of selected accessible tumor lesions from patients treated with tremelimumab were examined to further elucidate the mechanism of its antitumor activity...
  17. ncbi request reprint Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice
    Antoni Ribas
    Division of Hematology Oncology, Department of Medicine, University of California, Los Angeles, 90095, USA
    Cancer Immunol Immunother 55:663-71. 2006
    ..3) In sensitive targets a putative activating NK ligand in DC-stimulated NK cells from CD8alphaKO mice signals directly to PI3-K, but is distinct from NKG2D...
  18. pmc Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy
    Chao Ma
    NanoSystems Biology Cancer Center, Division of Physics, California Institute of Technology, Pasadena, CA 91125, USA
    Cancer Discov 3:418-29. 2013
    ..This study highlights the need to develop approaches to maintaining antitumor T-cell functionality with the aim of increasing the long-term efficacy of TCR-engineered ACT immunotherapy...
  19. ncbi request reprint Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)
    Lana Y Schumacher
    Department of Surgery, Division of Surgical Oncology, University of California, Los Angeles 90095, USA
    J Immunol 176:4757-65. 2006
    ..In conclusion, the proteasome inhibitor bortezomib can pharmacologically sensitize tumor cells to the lytic effects of DC-activated immune effector cells...
  20. pmc A beta-camera integrated with a microfluidic chip for radioassays based on real-time imaging of glycolysis in small cell populations
    Nam T Vu
    Crump Institute for Molecular Imaging, University of California, Los Angeles, California 90095 1770, USA
    J Nucl Med 52:815-21. 2011
    ..This paper demonstrates that the integrated system enables digital control and quantitative measurements of glycolysis in B-Raf(V600E)-mutated melanoma cell lines in response to specific B-Raf inhibition...
  21. ncbi request reprint Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays
    Begona Comin-Anduix
    Department of Surgery, Division of Surgical, University of California at Los Angeles, Los Angeles, California, USA
    Clin Cancer Res 12:107-16. 2006
    ..Define an immunologic response using the tetramer and enzyme-linked immunospot (ELISPOT) assays...
  22. ncbi request reprint Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
    Antoni Ribas
    Department of Medicine, Division of Hematology Oncology Surgery, University of California at Los Angeles, CA, USA
    J Clin Oncol 23:8968-77. 2005
    ..A phase I trial was conducted to test the safety of CP-675,206...
  23. pmc Immunomodulation by imiquimod in patients with high-risk primary melanoma
    Rupa Narayan
    Division of Dermatology, Los Angeles Biomedical Research Institute, Harbor UCLA Medical Center, Torrance, California 90502, USA
    J Invest Dermatol 132:163-9. 2012
    ..Further research into TLR7 immunomodulating pathways as a basis for effective immunotherapy against melanoma in conjunction with surgery is warranted...